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BACKGROUND: Preterm birth is the leading cause of neonatal hydroxyprogesterone caproate initiation and preterm birth <37 weeks’
morbidity and mortality in nonanomalous neonates in the United States.
Women with a previous early spontaneous preterm birth are at highest risk
for recurrence. Weekly intramuscular 17-alpha hydroxyprogesterone
caproate reduces the risk of recurrent prematurity. Although current
guidelines recommend 17-alpha hydroxyprogesterone caproate initiation
between 16 and 20 weeks, in clinical practice, 17-alpha hydrox-
yprogesterone caproate is started across a spectrum of gestational ages.
OBJECTIVE: The objective of the study was to examine the relationship
between the gestational age at 17-alpha hydroxyprogesterone caproate
initiation and recurrent preterm birth among women with a prior sponta-
neous preterm birth 16e28 weeks’ gestation.
STUDYDESIGN: This was a retrospective cohort study of women from
a single tertiary care center, 2005e2016. All women with 1 singleton
preterm births because of a spontaneous onset of contractions, preterm
prelabor rupture of membranes, or painless cervical dilation between 16
and 28 weeks followed by a subsequent singleton pregnancy treated with
17-alpha hydroxyprogesterone caproate were included. Women were
grouped based on quartiles of gestational age of 17-alpha hydrox-
yprogesterone caproate initiation (quartile 1, 140/7 to 161/7; quartile 2,
162/7 to 170/7; quartile 3, 171/7 to 186/7; and quartile 4, 190/7 to 275/7).
Women with a gestational age of 17-alpha hydroxyprogesterone caproate
initiation in quartiles 1 and 2 were considered to have early-start 17-alpha
hydroxyprogesterone caproate; those in quartiles 3 and 4 were considered
to have late-start 17-alpha hydroxyprogesterone caproate. The primary
outcome was recurrent preterm birth <37 weeks’ gestation. Secondary
outcomes included recurrent preterm birth <34 and <28 weeks’
gestation and composite major neonatal morbidity (diagnosis of grade III or
IV intraventricular hemorrhage, periventricular leukomalacia, broncho-
pulmonary dysplasia, necrotizing enterocolitis stage II or III, or death).
Gestational age at delivery was compared by quartile of 17-alpha
hydroxyprogesterone caproate initiation using Kaplan-Meier survival
curves and the log-rank test. Logistic regression models estimated odds
ratios for the association between gestational age at 17-alphagestation, adjusting for demographics, prior pregnancy and antenatal
characteristics.
RESULTS: A total of 132 women met inclusion criteria; 52 (39.6%)
experienced recurrent preterm birth<37 weeks in the studied pregnancy.
17-Alpha hydroxyprogesterone caproate was initiated at a mean 176/7 
2.5 weeks. Demographic and baseline characteristics were similar be-
tween women with early-start 17-alpha hydroxyprogesterone caproate
(quartiles 1 and 2) compared with those with late-start 17-alpha
hydroxyprogesterone caproate (quartiles 3 and 4). Women with early-
start 17-alpha hydroxyprogesterone caproate trended toward lower
rates of recurrent preterm birth <37 weeks compared with those with
late-start 17-alpha hydroxyprogesterone caproate (41.3% vs 57.7%, P¼
.065). Delivery gestational age was inversely proportional to gestational
age at 17-alpha hydroxyprogesterone caproate initiation (quartile 1, 374/7
weeks vs quartile 2, 365/7 vs quartile 3, 361/7 weeks vs quartile 4, 340/7,
P¼ .007). In Kaplan-Meier survival analyses, these differences in delivery
gestational age by 17-alpha hydroxyprogesterone caproate initiation
quartile persisted across pregnancy (log-rank P < .001). In regression
models, later initiation of 17-alpha hydroxyprogesterone caproate
was significantly associated with increased odds of preterm birth
<37 weeks. Women with early 17-alpha hydroxyprogesterone caproate
initiation also had lower rates of major neonatal morbidity than those with
later 17-alpha hydroxyprogesterone caproate initiation (1.5% vs 14.3%,
P ¼ .005).
CONCLUSION: Rates of recurrent preterm birth among women with a
prior spontaneous preterm birth 16e28 weeks are high. Women
beginning 17-alpha hydroxyprogesterone caproate early deliver later
and have improved neonatal outcomes. Clinicians should make every
effort to facilitate 17-alpha hydroxyprogesterone caproate initiation at
16 weeks.
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spontaneous preterm birthreterm birth (PTB) continues to beP the leading cause of neonatal
morbidity and mortality. Prematurity is
the leading cause of death in childrenunder age 5 years and contributes to
short- and long-term disability in
countless survivors.1,2
In the United States, after a brief
period of decline, the rates of PTB
increased between 2014 and 2015 and
remain unacceptably high, at 9.6%.1
Unfortunately, recent trends toward a
decline in overall PTB rates have not
been consistent across all gestational
ages, and the rate of early PTB (<34
weeks’ gestation) has remained static, at
3.41% in 2012 (up from 3.32% in1990).2 Although early PTB affects
smaller numbers of neonates, those born
<34 weeks are more likely to die in the
first year of life. Survivors of early PTB
are at greatest risk for increased utiliza-
tion of resources in early life, need for
early intervention services, and reduced
school performance compared with ba-
bies born late preterm or at term.3-8
A history of a prior spontaneous PTB
is the greatest risk factor predicting risk
for recurrence. This risk is even greater
among women with multiple prior PTB
and those with a prior early PTB,
including caused by a cervical insuffi-
ciency phenotype.9-12 Furthermore, PTB
tends to recur at similar gestational
ages13-15; thus, women with a prior early
PTB are at highest risk for significant
recurrent neonatal morbidity and mor-
tality in subsequent pregnancies.
Intramuscular 17-alpha hydrox-
yprogesterone caproate (17-OHPC) in-
jections administered weekly beginning
at 16e20 weeks until 36 weeks of gesta-
tion reduce the risk of recurrent PTB
(relative risk, 0.66; 95% confidence in-
terval, 0.54e0.81)16 and may be most
efficacious among women with a prior
early PTB.17,18 Current clinical guide-
lines recommend initiation of 17-OHPC
therapy between 16 and 20 weeks’
gestation amongwomenwith a singleton
gestation and a prior spontaneous PTB;
these recommendations largely mirror
the protocol followed by Meis et al16 in
the large randomized controlled trial of
17-OHPC vs placebo published in
2003.19,20
In broader obstetric populations of
women with a prior spontaneous PTB
<37 weeks’ gestation, results of studies
examining the impact of gestational age
of 17-OHPC on pregnancy outcomes
have been mixed, and some reports have
suggested beneficial effects with 17-
OHPC initiated as late as 28 weeks’
gestation.21
The purpose of this study was to
examine the relationship between the
gestational age at 17-OHPC initiation
and recurrent spontaneous PTB among
women at high risk for recurrent PTB:
those with a history of spontaneous PTB
16e28 weeks’ gestation.
Materials and Methods
This is a retrospective cohort of women
delivering at University of North Car-
olina (UNC) Hospitals from 2005
through 2016. We included women with
1 previous documented singleton
nonanomalous delivery between 16
and 28 weeks’ gestation because of
spontaneous indications who received at
least 1 dose of 17-OHPC prophylaxis in a
subsequent singleton pregnancy with
delivery of that subsequent pregnancy at
UNC.We defined spontaneous PTB as de-
livery following preterm prelabor
rupture of membranes, idiopathic pre-
term labor (painful uterine contractions
leading to cervical dilation and eventual
delivery), or cervical insufficiency
(painless dilation of the cervix in mid-
pregnancy, or asymptomatic cervical
shortening <25 mm prior to 24 weeks’
gestation with subsequent delivery at
<28 weeks) as documented in the
medical record.
Women whose index delivery at <28
weeks was due to medical or fetal in-
dications (eg, because of preeclampsia or
fetal indications such as growth restric-
tion) or was spontaneous but compli-
cated by major fetal anomalies or
aneuploidy were excluded. Gestational
age was determined from standard al-
gorithms using the last menstrual period
and ultrasound criteria.22
Women were initially identified by
searching diagnostic and discharge codes
from the UNC Perinatal Database, an
established, comprehensive registry of
women including all women delivering
at UNC. Only the most recent subse-
quent pregnancy was considered for
women who had multiple pregnancies
following the index spontaneous PTB at
<28 weeks.
Prenatal care was provided at the
discretion of the clinician, with consul-
tation or primary management by
maternal-fetal medicine providers as
needed. The UNC Division of Maternal-
Fetal Medicine publishes online algo-
rithms as a service to providers in North
Carolina to assist the primary obstetric
provider in the clinical management of a
variety of pregnancy complications and
standardized care throughout the state
(www.mombaby.org).
Electronic medical records were
manually verified and abstracted to
ensure eligibility and to obtain addi-
tional clinical data for this study. This
study was approved by the Institutional
Review Board at the University of North
Carolina at Chapel Hill.
Gestational age of 17-OHPC initiation
was abstracted and categorized into
quartiles (quartile 1, 140/7 to 161/7;
quartile 2, 162/7 to 170/7; quartile 3, 171/7
to 186/7; quartile 4, 190/7 to 275/7).Women with a gestational age of 17-
OHPC initiation in quartiles 1 and 2
were considered to have early-start 17-
OHPC, and those in quartiles 3 and 4
were considered to have late-start 17-
OHPC. Demographic, obstetric history,
and antenatal characteristics were
compared between women with early-
and late-start 17-OHPC. This included
assessing the timing of prenatal care
initiation and gestational age at the first
obstetric ultrasound.
The primary outcomewas PTB at<37
weeks’ gestation. Secondary outcomes
included PTB at <34 and <28 weeks’
gestation and composite neonatal
morbidity (defined as 1 or more of the
following prior to initial hospital
discharge: grade III or IV intraventric-
ular hemorrhage, periventricular leuko-
malacia, bronchopulmonary dysplasia,
necrotizing enterocolitis requiring sur-
gery, or death).
Kaplan-Meier survival curves were
used to compare the gestational age at
delivery by quartile of 17-OHPC initia-
tion and were compared with the log-
rank test. Bivariate analyses comparing
cohort characteristics and neonatal out-
comes by early and late start were con-
ducted using c2, Fisher exact, and
analysis of variance, as appropriate. Lo-
gistic regression models estimated odds
ratios for the association between quar-
tiles of 17-OHPC initiation and PTB
<37 weeks.
Stepwise regression with backward
elimination was performed to select an
adjusted model. We initially included all
variables significant in bivariate analyses;
those factors with P < .20 were retained
in final regression models. Further vari-
ables were excluded until no further
significant change in the final model was
noted based on R2. All analyses were
performed using STATA version 13.1
(College Station, TX).
Results
A total of 132 women met inclusion
criteria. 17-OHPC was initiated at a
mean 176/7  2.5 weeks (median 170/7
weeks, interquartile range 162/7 to 186/7
weeks). Ninety-five women (72.0%)
initiated 17-OHPC within the recom-
mended 16e20 week gestational age
window, whereas 15 (11.3%) started at
less than 16 weeks and 22 (16.7%) began
17-OHPC at 20 weeks.
Demographic and baseline character-
istics were similar between 69 women
with early-start 17-OHPC and 63 with
late-start 17-OHPC; specifically, there
were no differences in race, prepreg-
nancy body mass index, delivery gesta-
tional age of the penultimate pregnancy,
number of pregnancies after the index
<28 week PTB, or rate of cerclage
placement in the current gestation
(Table 1). However, women with early-
start 17-OHPC were more likely to be
married (Table 1).TABLE 1




Prepregnancy BMI 30 kg/m2
Gestational age of earliest prior PTB (mean weeks
Delivery gestational age of penultimate pregnan
reaching 14 weeks (mean weeks,  SD)
History of 1 prior term deliveries
Number of previous PTB <37 weeks’ gestation
(median, IQR)
History of cervical insufficiency in 1 prior preg
Number of pregnancies after index <28 wks PT
(median, IQR)
First prenatal visit or initial obstetric ultrasound
weeks’ gestation
First prenatal visit or initial obstetric ultrasound
weeks’ gestation
Primary site of prenatal care was University of N
Carolina hospitals and clinics
Received some or all prenatal care with matern
medicine physician this pregnancy
Cervical length <25 mm during current pregnan
Cerclage placed this pregnancy
Received vaginal progesterone >14 wks this pre
Received antenatal corticosteroids
BMI, body mass index; IQR, interquartile range; 17-OHPC, 17-a
a Among 98 women with at least 1 transvaginal ultrasound asse
Ning et al. Gestational age of 17-OHPC initiation and risk of recThe vast majority of women (92.2%)
received prenatal care and/or had an
obstetrical ultrasound prior to 16 weeks;
only 2 (1.7%) initiated care at 20
weeks. Less than half were cared for
primarily by a maternal-fetal medicine
physician, a proportion that did not
differ by 17-OHPC initiation group, but
women with late start were less likely to
receive their prenatal care primarily at
UNCHospitals and clinics, although this
did not reach statistical significance
(Table 1). Nearly half of women (47%)
had a history of cervical insufficiency
prior to the studied pregnancy, and 54/
132 (41%) had a cerclage placed duringtenatal characteristics
Early 17-OHPC initiation
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ssment of cervical length prior to 24 weeks’ gestation.
urrent PTB. Am J Obstet Gynecol 2017.pregnancy; rates of cervical insufficiency
and cerclage placement were similar in
the early- and late-start 17-OHPC
groups (Table 1). Of note, Table 1 find-
ings were similar when all 4 quartiles
were compared instead of collapsing
groups into early- and late-start 17-
OHPC groups.
Fifty-two women (39%) delivered at
<37 weeks. Recurrent PTB at<37 weeks
was less common among women with
early-start 17-OHPC compared with
those with late-start 17-OHPC, 41.3% vs
57.7% (P ¼ .065), although this did not
reach statistical significance (Table 2).
However, women with early-start 17-Late 17-OHPC initiation
(Q3 and Q4), 172/7 to 275/7
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TABLE 2
Pregnancy and neonatal outcomes by gestational age at 17-OHPC initiation
Variables
Early 17-OHPC initiation
(Q1 and Q2), 140/7 to 171/7
(n ¼ 69)
Later 17-OHPC initiation
(Q3 and Q4), 17w2d to 28w0d
(n ¼ 63) P value
Delivery gestational age (weeks  SD) 37.0  3.1 35.0  5.1 .008
Developed gestational diabetes 5 (7.3) 5 (7.9) > .990
Preeclampsia or gestational hypertension 3 (4.4) 3 (4.8) > .990
Vaginal delivery 32 (46.4) 29 (46.0) .968
Birthweight (grams  SD) 2908  775 2507  1035 .012
Delivered <37 wks 22 (31.9) 30 (47.6) .065
Delivered <34 wks 10 (14.5) 18 (28.6) .048
Delivered <28 wks 1 (1.5) 8 (12.7) .014
Male infant 37 (54.4) 29 (46.0) .338
Intraventricular hemorrhage, grade I or II 1 (1.5) 1 (1.6) > .990
Major neonatal morbidity 1 (1.5) 9 (14.3) .007
Neonatal death 1 (1.5) 4 (6.4) .192
Bronchopulmonary dysplasia 0 (0) 4 (6.4) .049
Intraventricular hemorrhage, grade III or IV 0 (0) 1 (1.6) .480
Periventricular leukomalacia 0 (0) 1 (1.6) .477
Necrotizing enterocolitis, stage II or III 0 (0) 2 (3.2) .226
17-OHPC, 17-alpha hydroxyprogesterone caproate; PTB, preterm birth; Q, quartile.
Ning et al. Gestational age of 17-OHPC initiation and risk of recurrent PTB. Am J Obstet Gynecol 2017.OHPC had a later mean delivery gesta-
tional age (37.0 3.1 weeks vs 35.0 5.1
weeks for women with late-start 17-
OHPC [P ¼ .008]).
These differences in rates of recurrent
PTB <37 weeks and delivery gestational
age by 17-OHPC start were even more
pronounced when examining quartiles,
in which both rates of recurrent PTB at
<37 weeks (quartile 1, 21.2% vs quartile
2, 41.7% vs quartile 3, 43.3% vs quartile
4, 51.5% preterm<37 weeks [P¼ .076])
and delivery gestational age were
consistently inversely proportional to
gestational age at 17-OHPC initiation
(quartile 1, 374/7 weeks vs quartile
2, 365/7 vs quartile 3, 361/7 weeks vs
quartile 4, 340/7 [P ¼ .007]).
Differences in mean delivery gesta-
tional age were statistically significant
across gestation in the Kaplan-Meier
survival curve (log rank P < .001;
Figure). Similar findings were appreci-
ated for recurrent PTB at <34 and <28
weeks’ gestation (Table 2). Rates of ma-
jor composite neonatal morbidity werehigher among women with late-start 17-
OHPC initiation (Table 2).
In logistic regression models, later
initiation of 17-OHPC was associated
with increased odds of PTB when
adjusting for confounders (Table 3).
Each later quartile of initiation was
associated with an elevated risk
compared with the first quartile, which
served as the referent group. Women
with a short cervical length (<25mm) in
the midtrimester also were at increased
risk for recurrent PTB in the model;
women with a prepregnancy body mass
index 30 kg/m2 and those with the
earliest prior gestational ages of their
earliest prior deliveries had a decreased
risk for recurrent PTB in the final model
(Table 3).
Comment
We found that women with a prior
singleton spontaneous PTB at <28
weeks are at high risk for recurrent PTB
at <37 weeks’ gestation despite 17-
OHPC therapy. Individuals whoinitiated 17-OHPC therapy at earlier
gestational ages had the lowest recur-
rence of PTB across a spectrum of
gestational ages. These differences were
observed despite the overwhelming
majority (>90%) initiating prenatal care
or having an initial obstetric ultrasound
prior to 16 weeks’ gestation. Thus, these
very high-risk women entered care early
and most had the opportunity to begin
17-OHPC prophylaxis within the rec-
ommended time of 16e20 weeks’
gestation. Despite this, 16% initiated 17-
OHPC after 20 weeks.
Other studies have investigated the
relationship between gestational age at
17-OHPC initiation and delivery gesta-
tional age in obstetric cohorts that
included women with a prior sponta-
neous PTB up to 36 weeks’ gestation.
How et al23 evaluated 599 women initi-
ating 17-OHPC between 16 and 21
weeks and 307 women initiating 17-
OHPC between 21 and 27 weeks and
found no significant difference in spon-
taneous PTB at<37 weeks between the 2
FIGURE
Probability of remaining pregnant by gestational age at 17-OHPC initiation
17-OHPC, 17-alpha hydroxyprogesterone caproate.
Ning et al. Gestational age of 17-OHPC initiation and risk of recurrent PTB. Am J Obstet Gynecol 2017.groups (33% vs 36%), <35 weeks (16%
vs 17%), or <32 weeks (6% vs 4%).
In contrast, Gonzalez-Quintero et al24
studied 156 women initiating 17-OHPC
at 16e20 weeks and compared themTABLE 3
Adjusted odds ratios for the associatio
preterm birth <37 weeks among wome
week deliveries
Variables
Gestational age at start of 17-OHPC
Q1, 140/7 to 162/7
Q2, 162/7 to 170/7
Q3, 171/7 to 186/7
Q4, 190/7 to 275/7
Cervical length <25 mm
Prepregnancy body mass index 30 kg/m2
Gestational age of earliest prior delivery
(per week of completed pregnancy)
CI, confidence interval; 17-OHPC, 17-alpha hydroxyprogesteron
a Additional factors considered in the model were black race, ce
delivery, and marital status; these factors were excluded from
Ning et al. Gestational age of 17-OHPC initiation and risk of recwith 119 women initiating 17-OHPC
between 21 and 26 weeks and noted
lower rates of spontaneous PTB among
those initiating therapy earlier (in the
16e20 week time period; 26% vs 37%n between 17-OHPC initiation and
n with ‡1 prior spontaneous 16e28
Adjusted odds ratio
for PTB (95% CI)a P value
1.0 (referent) —
4.2 (1.3, 13.7) .020
4.3 (1.3, 14.6) .019
5.3 (1.6, 17.5) .006
4.2 (1.2, 15.0) .027
0.4 (0.2, 0.9) .028
0.9 (0.8, 1.0) .045
e caproate; PTB, preterm birth; Q, quartile.
rclage in current pregnancy, gestational age of penultimate
the final model (all P  .20).
urrent PTB. Am J Obstet Gynecol 2017.[P ¼ .065]) within the overall cohort.
Furthermore, a significant reduction in
PTB with earlier initiation was noted
among the subset of women who had
more than 1 prior PTB (27% vs 39%
[P ¼ .039]).24
However, neither of these studies
examined the gestational age of the
earliest prior PTB as a risk factor influ-
encing outcomes in relation to the
initiation of 17-OHPC, which may be a
possible explanation for the difference in
our results and those of How et al.23
Limited studies of prematurity spe-
cialty clinics have demonstrated
improved outcomes with reductions in
the rate of PTB among women provided
with specific education, frequent visits,
and treatment with consistent evidence-
based algorithms.25-27 Iams and col-
leagues28 recently examined data from a
prematurity clinic in Ohio, which pro-
vided accelerated access to prenatal care
for women with a prior spontaneous
PTB. In that clinic, earlier access to care
facilitated earlier initiation of 17-OHPC,
and rates of recurrent prematurity
dropped. However, it was difficult to
disentangle the effects of early, focused
prenatal care (likely received by the
women who started 17-OHPC early)
from the effects of early initiation of 17-
OHPC. The majority of women in this
cohort (73.0%) initiated prenatal care in
the first trimester, and 92.2% initiated
prenatal care or had an initial obstetric
ultrasound by 16 weeks’ gestation. This
suggests that the correlation we have
noted between earlier 17-OHPC initia-
tion and later delivery gestational age
and improved neonatal outcomes is not
due merely to earlier prenatal care.
Our study has several limitations.
Quartiles of gestational age at 17-OHPC
initiation were defined by the distribu-
tion of 17-OHPC initiation in this pop-
ulation. However, similar methodology
has been utilized in other studies of
prematurity to evaluate the relationship
between an exposure and an outcome
when the ideal cutoff for the exposure is
uncertain but a dose-response effect is
suspected.29 Furthermore, the majority
of women in the first quartile of gesta-
tional age at 17-OHPC initiation began
therapy prior to the American College of
 
Obstetricians and Gynecologists’s rec-
ommended start time of 16 weeks’
gestation. Although there is no evidence
to suggest that initiation prior to 16
weeks is associated with harm, efficacy
with initiation <16 weeks has not been
evaluated in high-quality randomized
controlled trials and therefore cannot be
recommended based on the results of the
current analysis.
The number of subjects in each
quartile of 17-OHPC administration
may limit the precision of the estimated
effect as demonstrated by the wide con-
fidence interval. Further investigation
with a greater sample size may clarify the
trends in influence in 17-OHPC initia-
tion over gestational ages or may suggest
an optimal gestational age cutpoint for
maximal 17-OHPC effect.
Finally, we did not have consistent
information regarding the number of
prenatal visits attended to evaluate the
effects of prenatal care and 17-OHPC
compliance on pregnancy outcomes,
given the variable locations of prenatal
care in this cohort. The lack of avail-
ability of specific prenatal care in this
data set also limits investigation into
reasons to explain the variability in
timing of initiation of 17P.
Our study has several strengths. This
is a relatively large cohort of womenwith
a very high a priori risk for recurrent
PTB. We had detailed information on
demographics and prior pregnancies
and were able to confirm that the prior
PTB were due to spontaneous in-
dications. We have provided evidence of
improved outcomes when 17-OHPC is
started earlier in pregnancy. Beginning
17-OHPC at 16 weeks’ gestation is a
simple recommendation with potential
for a clinically significant impact on
pregnancy outcomes, the timing of
which can be easily facilitated at the time
of the initial prenatal visit.
In conclusion, women with a prior
PTB at 16e28 weeks’ gestation are at
high risk for recurrent PTB in subse-
quent pregnancies. Outcomes are
improved when 17-OHPC is initiated
between 14 and 171/7 weeks’ gestation, a
time frame including the lower end of
the gestational age window recom-
mended by the American College ofObstetricians and Gynecologists and 
the Society of Maternal-Fetal Medicine. 
Clinicians should make every effort to 
facilitate 17-OHPC initiation at 16 
weeks. Future studies should confirm 
these findings, elucidate the potential 
mechanisms behind these effects, and 
evaluate whether earlier initiation (eg, 
14e16 weeks) may be more appro-
priate for certain subsets of women, 
including those at highest risk for
recurrent PTB. 
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